We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New X-Ray Crystallography Study Confirms Structure of Empty Cowpea mosaic virus Particles

By LabMedica International staff writers
Posted on 10 Apr 2016
Print article
Image: A study shows that a hollowed-out version of Cowpea mosaic virus could be useful in human therapies (Photo courtesy of the Scripps Research Institute).
Image: A study shows that a hollowed-out version of Cowpea mosaic virus could be useful in human therapies (Photo courtesy of the Scripps Research Institute).
An X-ray crystallography study confirmed that empty Cowpea mosaic virus (CPMV) particles (eVLPs) were structurally similar to the intact virus and showed that they could be used for drug transport and other biomedical applications.

CPMV is a plant virus of the Comovirus group. Its genome consists of two molecules of positive-sense RNA, which are separately encapsulated. The virus particles are 28 nanometers in diameter and contain 60 copies each of a Large (L) and Small (S) coat protein. The structure is well characterized to atomic resolution, and the viral particles are thermostable. CPMV displays a number of features that can be exploited for nanoscale biomaterial fabrication. Its genetic, biological, and physical properties are well characterized, and it can be isolated readily from plants. There are many stable mutants already prepared that allow specific modification of the capsid surface. It is possible to attach a number of different chemicals to the virus surface and to construct multilayer arrays of such nanoparticles on solid surfaces. This gives the natural or genetically engineered nanoparticles a range of properties which could be useful in nanotechnological applications such as biosensors, catalysis and nanoelectronic devices.

Empty CPMV particles (eVLPs) can be modified to entrap drugs or other molecules while the outside surface can be coated with peptides that direct the particles to a specific class of target cells.

Investigators at The Scripps Research Institute (La Jolla, CA, USA) reported in the March 24, 2016, online edition of the journal Structure that they had used X-ray crystallography at 2.3 angstrom resolution to determine the crystal structure of CPMV eVLPs and then compared it to previously reported cryo-electron microscopy (cryo-EM) reports of eVLPs and virion crystal structures.

The new study revealed that although the X-ray and cryo-EM structures of eVLPs were mostly similar, there existed significant differences at the C-terminus of the small (S) subunit. The intact C-terminus of the S subunit plays a critical role in enabling the efficient assembly of CPMV virions and eVLPs, but undergoes proteolysis after particle formation. In addition, the results of mass spectrometry-based proteomics analysis of coat protein subunits from CPMV eVLPs and virions showed that the C-termini of S subunits underwent proteolytic cleavages at multiple sites instead of a single cleavage site as previously observed.

"By studying the structure of the viral particles, we can get important information for transforming this plant virus into a useful therapeutic," said senior author Dr. Vijay Reddy, an associate professor at The Scripps Research Institute. "The eVLP is no longer a virus; it is just a protein capsule."

Related Links:

The Scripps Research Institute


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.